Table 3.
History of advanced therapy (within 12 months pre-index) in patients with PsA initiating tofacitinib
| Patients with PsA initiating tofacitinib (N = 318) |
|
|---|---|
| Patients exposed to advanced therapy, n (%)a | |
| Any advanced therapy | 243 (76.4) |
| Secukinumab | 92 (28.9) |
| Adalimumab | 59 (18.6) |
| Apremilast | 59 (18.6) |
| Etanercept | 47 (14.8) |
| Ustekinumab | 36 (11.3) |
| Certolizumab | 20 (6.3) |
| Ixekizumab | 15 (4.7) |
| Abatacept | 10 (3.1) |
| Golimumab | 8 (2.5) |
| Infliximab | 1 (0.3) |
| Number of unique advanced therapy prescriptions per patient | |
| Mean (SD) | 1.1 (0.8) |
| Median (IQR) | 1 (1–2) |
| Range | 0–4 |
| Patients with specified number of unique advanced therapies, n (%) | |
| 0 | 75 (23.6) |
| 1 | 155 (48.7) |
| 2 | 73 (23.0) |
| ≥ 3 | 15 (4.7) |
bDMARD biologic DMARD, DMARD disease-modifying antirheumatic drug, IQR interquartile range, N number of patients in each cohort, n number of patients in each category, PsA psoriatic arthritis, SD standard deviation
aPatients with at least one claim for bDMARDs or apremilast within 12 months pre-index